Sector Gamma AS Has $2.15 Million Stock Position in Organon & Co. $OGN

Key Points

• Sector Gamma AS cut its Organon stake by 44.8% in the fourth quarter, selling 243,711 shares and leaving it with 300,000 shares valued at about $2.15 million.
• Analyst sentiment remains cautious: the stock’s consensus rating is currently “Reduce,” with an average price target of $11.40, though several firms recently upgraded or raised targets to neutral/hold.
• Organon reported mixed quarterly results, missing EPS and revenue estimates for the latest quarter, even as the stock traded near its 52-week high of $13.49 and management continued its small quarterly dividend of $0.02 per share.

Sector Gamma AS decreased its stake in Organon & Co. (NYSE:OGN - Free Report) by 44.8% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 300,000 shares of the company's stock after selling 243,711 shares during the quarter. Sector Gamma AS owned 0.12% of Organon & Co. worth $2,151,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Foster Dykema Cabot & Partners LLC acquired a new position in shares of Organon & Co. in the 3rd quarter valued at $29,000. Farther Finance Advisors LLC boosted its position in shares of Organon & Co. by 87.8% in the 4th quarter. Farther Finance Advisors LLC now owns 4,349 shares of the company's stock valued at $31,000 after purchasing an additional 2,033 shares during the period. Rothschild Investment LLC boosted its position in shares of Organon & Co. by 73.1% in the 3rd quarter. Rothschild Investment LLC now owns 3,899 shares of the company's stock valued at $42,000 after purchasing an additional 1,646 shares during the period. Eurizon Capital SGR S.p.A. acquired a new position in shares of Organon & Co. in the 4th quarter valued at $44,000. Finally, Smartleaf Asset Management LLC boosted its position in shares of Organon & Co. by 70.2% in the 3rd quarter. Smartleaf Asset Management LLC now owns 5,113 shares of the company's stock valued at $53,000 after purchasing an additional 2,109 shares during the period. Institutional investors and hedge funds own 77.43% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the company. Zacks Research upgraded Organon & Co. from a "strong sell" rating to a "hold" rating in a research report on Tuesday, April 14th. Barclays raised their price objective on Organon & Co. from $7.50 to $8.00 and gave the stock an "underweight" rating in a research report on Tuesday, February 24th. Weiss Ratings upgraded Organon & Co. from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Friday, May 15th. BNP Paribas Exane restated a "neutral" rating and set a $14.00 price objective (up from $12.00) on shares of Organon & Co. in a research report on Wednesday, April 29th. Finally, Piper Sandler upgraded Organon & Co. from an "underweight" rating to a "neutral" rating and raised their price objective for the stock from $5.00 to $14.00 in a research report on Tuesday, April 28th. Five investment analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company's stock. According to MarketBeat.com, Organon & Co. currently has a consensus rating of "Reduce" and an average price target of $11.40.

Organon & Co. Trading Up 0.7%

Shares of NYSE OGN opened at $13.48 on Friday. Organon & Co. has a one year low of $5.69 and a one year high of $13.49. The firm has a market capitalization of $3.54 billion, a PE ratio of 14.49, a PEG ratio of 1.24 and a beta of 1.55. The company has a current ratio of 1.97, a quick ratio of 1.42 and a debt-to-equity ratio of 9.47. The business has a 50-day moving average price of $11.47 and a two-hundred day moving average price of $8.86.

Organon & Co. (NYSE:OGN - Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The company reported $0.71 EPS for the quarter, missing analysts' consensus estimates of $0.83 by ($0.12). Organon & Co. had a return on equity of 99.95% and a net margin of 3.99%.The business had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.49 billion. During the same quarter in the previous year, the business posted $1.02 earnings per share. The company's revenue was down 3.5% compared to the same quarter last year. As a group, analysts predict that Organon & Co. will post 3.23 earnings per share for the current fiscal year.

Organon & Co. Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, June 11th. Stockholders of record on Monday, May 11th were issued a dividend of $0.02 per share. This represents a $0.08 annualized dividend and a dividend yield of 0.6%. The ex-dividend date was Monday, May 11th. Organon & Co.'s payout ratio is currently 8.60%.

Insider Activity

In other news, SVP Lynette Holzbaur purchased 26,448 shares of Organon & Co. stock in a transaction dated Wednesday, May 6th. The stock was acquired at an average cost of $13.35 per share, for a total transaction of $353,080.80. Following the acquisition, the senior vice president directly owned 52,851 shares in the company, valued at $705,560.85. This represents a 100.17% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 1.62% of the stock is currently owned by corporate insiders.

About Organon & Co.

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.